RELENZA

Compare RELENZA  to:
Compare
Compare
RELENZA (Zanamivir) 5mg/blister oral inhalation from GlaxoSmithKline

Generic Name for RELENZA

Zanamivir 5mg/blister; dry pwd for oral inhalation; contains lactose.

Legal Classification:

Rx

Pharmacological Class for RELENZA

Neuraminidase inhibitor.

Manufacturer of RELENZA

GlaxoSmithKline Pharmaceuticals

Indications for RELENZA

Treatment of uncomplicated acute illness due to influenza A and B virus in patients ≥7 years of age who have been symptomatic for no more than two days. Prophylaxis of influenza in patients ≥5 years of age.

Adults and Children:

Use supplied Diskhaler inhalation device. Complete course of treatment. Treatment: <7yrs: not recommended. ≥7yrs: 2 inh (10mg total) twice daily (at least 2 hrs apart) on 1st day; then 2 inh (10mg total) twice daily at 12-hr intervals for the next 4 days (5 days total). Prophylaxis: <5yrs: not recommended. ≥5yrs: 2 inh (10mg total) once daily. Household: use for 10 days. Community: use for 28 days.

Warnings/Precautions for RELENZA

Underlying airway disease (eg, asthma, COPD): not recommended; if used, patient must have a fast-acting bronchodilator available. Discontinue if bronchospasm or decline in respiratory function occurs or worsens. Monitor for signs of abnormal behavior (esp. in children). Pregnancy (Cat.C). Nursing mothers (unknown if drug excreted in milk).

Interactions for RELENZA

If an inhaled bronchodilator is scheduled for dosing at the same time, use the bronchodilator first. Caution with influenza virus vaccine live, intranasal (eg, FluMist); separate dosing by at least 48hrs before or 2 weeks after FluMist. May maintain normal influenza virus vaccine schedule.

Adverse Reactions for RELENZA

GI upset, sinusitis, dizziness, headache, bronchitis, cough, nasal symptoms, respiratory function decline (eg, bronchospasm, dyspnea), allergic reactions (eg, oropharyngeal edema), possible neuropsychiatric events (eg, seizures, confusion, abnormal behavior).

How is RELENZA supplied?

4 blisters/Rotadisk—5 Rotadisks/box (w. 1 Diskhaler)

Related Disease:

Influenza~antivirals

Related Resources

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions